TrialProceedings of the National Academy of Sciences of the United States of America2026

Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion.

Noor M Abdulkareem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.